The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Time to treatment doesn’t impact outcome in intensively treated newly diagnosed AML
Christoph Röllig, MD, MSc, of University Hospital Dresden, Dresden, Germany, explains how time from diagnosis to treatment does not affect outcome in intensively treated newly diagnosed acute myeloid leukemia (AML). This was determined through exploring the relationship between time between diagnosis, treatment and prognosis on a large set of real world data from the AML registry (NCT03188874) of the Study Alliance Leukemia (SAL) and comparing it to the published cohorts. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
